AVITA Medical（纳斯达克股票代码：RCEL）报告其季度每股亏损为 $(0.44)，低于分析师一致预期的 $(0.43)，差距为2.33%。与去年同期每股亏损$(0.28)相比，这一数字下降了57.14%。公司报告季度销售额为$18.41百万，低于分析师一致预期的$21.04百万，差距为12.53%。与去年同期的$14.20百万销售额相比，本季度销售额增长了29.67%。

以上内容来自Benzinga Earnings专栏，原文如下：

AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 57.14 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $18.41 million which missed the analyst consensus estimate of $21.04 million by 12.53 percent. This is a 29.67 percent increase over sales of $14.20 million the same period last year.